Case study reveals central retinal artery occlusion in a man with severe asthma, suggesting dupilumab's potential risks in eosinophilic granulomatosis with polyangiitis.
Dupilumab is widely used to treat type 2 inflammatory diseases; however, rare adverse events, including eosinophilic granulomatosis with polyangiitis (EGPA), may occur. We report the first case of central retinal artery occlusion (CRAO) as a manifestation of EGPA following dupilumab initiation after switching from mepolizumab in a 64-year-old man with severe asthma. The potential for rare but tragic complications such as CRAO should not be overlooked when using dupilumab, particularly when withdrawing or switching medications that suppress eosinophilic activity. Despite a generally poor visual prognosis, early recognition and multidisciplinary management are essential.
No takes yet. Share an insight, caveat, or question.
Matsumoto et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: